X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1294) 1294
Publication (111) 111
Magazine Article (13) 13
Book Review (11) 11
Book / eBook (3) 3
Book Chapter (3) 3
Conference Proceeding (3) 3
Trade Publication Article (3) 3
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1165) 1165
dideoxynucleosides - therapeutic use (800) 800
hiv infections - drug therapy (727) 727
anti-hiv agents - therapeutic use (526) 526
male (508) 508
female (498) 498
index medicus (448) 448
adult (421) 421
infectious diseases (354) 354
reverse transcriptase inhibitors - therapeutic use (339) 339
middle aged (326) 326
lamivudine - therapeutic use (322) 322
dideoxynucleosides - adverse effects (317) 317
drug therapy, combination (287) 287
pharmacology & pharmacy (264) 264
hiv (263) 263
abacavir (259) 259
anti-hiv agents - adverse effects (237) 237
zidovudine - therapeutic use (229) 229
dideoxynucleosides - administration & dosage (220) 220
animals (204) 204
treatment outcome (195) 195
immunology (193) 193
viral load (182) 182
hiv infections - virology (179) 179
hiv-1 - drug effects (165) 165
virology (163) 163
cd4 lymphocyte count (160) 160
dideoxynucleosides - pharmacology (160) 160
antiretroviral therapy (158) 158
drug combinations (156) 156
dideoxynucleosides (155) 155
tenofovir (143) 143
adenine - analogs & derivatives (140) 140
anti-hiv agents - administration & dosage (138) 138
lamivudine (136) 136
zidovudine (132) 132
aged (130) 130
antiviral agents (128) 128
adenine - therapeutic use (127) 127
reverse transcriptase inhibitors - adverse effects (127) 127
aids (126) 126
lamivudine - administration & dosage (126) 126
therapy (126) 126
hiv-1 (123) 123
hiv protease inhibitors - therapeutic use (121) 121
hiv-1 - genetics (115) 115
drug therapy (114) 114
hiv infection (111) 111
antiretroviral therapy, highly active (110) 110
dideoxynucleosides - pharmacokinetics (110) 110
hiv infections - immunology (104) 104
acquired immunodeficiency syndrome - drug therapy (100) 100
mice (99) 99
reverse transcriptase inhibitors - administration & dosage (99) 99
organophosphonates - therapeutic use (97) 97
rna, viral - blood (97) 97
positron-emission tomography (96) 96
microbiology (93) 93
benzoxazines (92) 92
oxazines - therapeutic use (85) 85
clinical trials as topic (83) 83
lamivudine - adverse effects (83) 83
oncology (83) 83
research (82) 82
antiviral agents - therapeutic use (79) 79
health aspects (79) 79
hiv infections - complications (79) 79
anti-hiv agents - pharmacology (78) 78
hla-b antigens - genetics (76) 76
mutation (76) 76
human-immunodeficiency-virus (75) 75
positron-emission-tomography (72) 72
zidovudine - administration & dosage (70) 70
adolescent (69) 69
protease inhibitors (67) 67
child (66) 66
human immunodeficiency virus--hiv (66) 66
radiology, nuclear medicine & medical imaging (66) 66
sulfonamides - therapeutic use (66) 66
efavirenz (65) 65
prospective studies (65) 65
time factors (65) 65
drug hypersensitivity - genetics (64) 64
emtricitabine (64) 64
risk factors (64) 64
genotype (63) 63
ritonavir - therapeutic use (63) 63
stavudine - therapeutic use (63) 63
antiretroviral drugs (62) 62
nevirapine - therapeutic use (62) 62
positron-emission tomography - methods (62) 62
retrospective studies (62) 62
care and treatment (61) 61
pharmacogenetics (61) 61
cell line, tumor (60) 60
drug administration schedule (60) 60
cancer (59) 59
didanosine - therapeutic use (59) 59
medicine & public health (59) 59
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1253) 1253
German (16) 16
Spanish (15) 15
French (13) 13
Italian (5) 5
Russian (3) 3
Chinese (2) 2
Dutch (1) 1
Hebrew (1) 1
Japanese (1) 1
Polish (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 01/2015, Volume 29, Issue 2, pp. 167 - 174
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety... 
MEDICINE, GENERAL & INTERNAL | THERAPY | NAIVE PATIENTS | RECOMMENDATIONS | EFAVIRENZ | TENOFOVIR DF | RESISTANCE | AIDS | SOCIETY-USA PANEL | LOPINAVIR/RITONAVIR | NELFINAVIR | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control
Journal Article
AIDS, ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Background: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for... 
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | tenofovir | antiretroviral therapy | NAIVE HIV-1-INFECTED PATIENTS | IMMUNOLOGY | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | lopinavir | ritonavir | RENAL-FAILURE | abacavir | SOCIETY-USA PANEL | INFECTED PATIENTS | 2008 RECOMMENDATIONS | FANCONI-SYNDROME | lamivudine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article
by Mugyenyi, P and Walker, AS and Hakim, J and Munderi, P and Gibb, DM and Kityo, C and Reid, A and Grosskurth, H and Darbyshire, JH and Ssali, F and Bray, D and Katabira, E and Babiker, AG and Gilks, CF and Kabuye, G and Nsibambi, D and Kasirye, R and Zalwango, E and Nakazibwe, M and Kikaire, B and Nassuna, G and Massa, R and Fadhiru, K and Namyalo, M and Zalwango, A and Generous, L and Khauka, P and Rutikarayo, N and Nakahima, W and Mugisha, A and Todd, J and Levin, J and Muyingo, S and Ruberantwari, A and Kaleebu, P and Yirrell, D and Ndembi, N and Lvagoba, F and Hughes, P and Aber, M and Lara, AM and Foster, S and Amurwon, J and Wakholi, BN and Whitworth, J and Wangati, K and Amuron, B and Kajungu, D and Nakiyingi, J and Omony, W and Tumukunde, D and Otim, T and Kabanda, J and Musana, H and Akao, J and Kyomugisha, H and Byamukama, A and Sabiiti, J and Komugyena, J and Wavamunno, P and Mukiibi, S and Drasiku, A and Byaruhanga, R and Labeja, O and Katundu, P and Tugume, S and Awio, P and Namazzi, A and Bakeinyaga, GT and Katabira, H and Abaine, D and Tukamushaba, J and Anywar, W and Ojiambo, W and Angweng, E and Murungi, S and Haguma, W and Atwiine, S and Kigozi, J and Namale, L and Mukose, A and Mulindwa, G and Atwiine, D and Muhwezi, A and Nimwesiga, E and Barungi, G and Takubwa, J and Mwebesa, D and Kagina, G and Mulindwa, M and Ahimbisibwe, F and Mwesigwa, P and Akuma, S and Zawedde, C and Nyiraguhirwa, D and Tumusiime, C and Bagaya, L and Namara, W and Karungi, J and Kankunda, R and ... and DART Trail Grp and DART Trial Team
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9709, pp. 123 - 131
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 3, Issue 3, p. CD005481
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2012, Volume 56, Issue 5, pp. 2305 - 2313
OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
ABACAVIR | LAMIVUDINE | SUBSTITUTION | DIDANOSINE | ZIDOVUDINE | IMMUNODEFICIENCY-VIRUS TYPE-1 | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | HIV-1-INFECTED PATIENTS | ANTIRETROVIRAL THERAPY | DRUG-RESISTANCE | TENOFOVIR | Genomics | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | HIV Reverse Transcriptase - genetics | Reverse Transcriptase Inhibitors - administration & dosage | Thymidine - therapeutic use | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Thymidine - administration & dosage | Adenine - therapeutic use | HIV-1 - isolation & purification | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Nucleosides - genetics | Reverse Transcriptase Inhibitors - therapeutic use | Dideoxynucleosides - administration & dosage | Drug Resistance, Multiple, Viral - drug effects | Adenine - analogs & derivatives | Drug Resistance, Multiple, Viral - genetics | Organophosphonates - therapeutic use | HIV-1 - drug effects | HIV Infections - virology | Genotype | HIV-1 - genetics | Adenine - administration & dosage | Organophosphonates - administration & dosage | Phenotype | Algorithms | Least-Squares Analysis | HIV Infections - drug therapy | Zidovudine - therapeutic use | Mutation | nucleosides | RNA-directed DNA polymerase | tenofovir | Abacavir | Data processing | Thymidine | Drug resistance | Statistics | Antiviral Agents
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 08/2006, Volume 26, Issue 8, pp. 1111 - 1133
The human immunodeficiency virus (HIV) was discovered in 1982, but treatment strategies were not introduced until 5 years later. Early regimens consisted of... 
antiretroviral agents | nucleoside reverse transcriptase inhibitors | HIV | human immunodeficiency virus | protease inhibitors | highly active antiretroviral therapy | NRTI | HAART | Highly active antiretroviral therapy | Protease inhibitors | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus | HIV PROTEASE INHIBITORS | COMBINATION THERAPY | REVERSE-TRANSCRIPTASE | EMTRICITABINE | CROSS-RESISTANCE | RANDOMIZED-TRIAL | TENOFOVIR DISOPROXIL FUMARATE | NAIVE PATIENTS | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS | EXPERIENCED PATIENTS | Humans | Organophosphates - therapeutic use | Drugs, Investigational - therapeutic use | Dideoxynucleosides | Reverse Transcriptase Inhibitors - administration & dosage | Oligopeptides - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | HIV Envelope Protein gp41 - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Anti-Retroviral Agents - therapeutic use | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Clinical Trials as Topic | HIV Protease Inhibitors - administration & dosage | Drug Resistance, Multiple, Viral | HIV Protease Inhibitors - therapeutic use | Antiretroviral Therapy, Highly Active | Animals | Sulfonamides - therapeutic use | Anti-Retroviral Agents - administration & dosage | Pyrones - therapeutic use | HIV Infections - drug therapy | Peptide Fragments - therapeutic use | Patient Compliance | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2009, Volume 361, Issue 23, pp. 2230 - 2240
Journal Article
by Sabin, Caroline A and Worm, Signe W and Weber, Rainer and Reiss, Peter and El-Sa, Wafaa and Dabis, Francois and de Wit, Stephane and Law, Matthew and D'Arminio Monforte, Antonella and Friis-Møller, Nina and Kirk, Ole and Pradier, Christian and Weller, Ian and Phillips, Anew N and Lundgren, Jens D and Collins, S and Dabis, F and d'Arminio Monforte, A and de Wit, S and El-Sa, W. M and Kirk, O and Law, M and Pradier, C and Phillips, A and Rosseau, F and Storfer, S. P and Weber, I and Lundgren, J. D and Worm, S. W and Friis-øller, N and Sabin, C. A and Sjøl, A and Sawitz, A and Rickenbach, M and Pezzotti, P and Krum, E and Gras, L and Balestre, E and Sundström, A and Poll, B and Fontas, E and Torres, F and Petoumenos, K and Kjaer, J and Hammer, S and Neaton, J and de Wolf, F and Zaheri, S and Bronsveld, W and Hillebrand-Haverkort, M. E and Prins, J. M and Bos, J. C and Eeftinck Schattenkerk, J. K. M and Geerlings, S. E and Godfried, M. H and Lange, J. M. A and van Leth, F. C and Lowe, S. H and van der Meer, J. T. M and Nellen, F. J. B and Pogány, K and van der Poll, T and Ruys, Th A and Sankatsing, Raaj R and Steingrover, R and van Twillert, G and van der Valk, M and van Vonderen, M. G. A and Vrouenraets, S. M. E and van Vugt, M and Wit, F. W. M. N and van Eeden, A and ten Veen, J. H and van Dam, P. S and Roos, J. C and Brinkman, K and Frissen, P. H. J and Weigel, H. M and Mulder, J. W and van Gorp, E. C. M and Meenhorst, P. L and Mairuhu, A. T. A and Veenstra, J and Danner, S. A and van Agtmael, M. A and Claessen, F. A. P and Perenboom, R. M and Rijkeboer, A and van Vonderen, M and Richter, C and van der Berg, J and van Leusen, R and Vriesendorp, R and Jeurissen, F. J. F and Kauffmann, R. H and Koger, E. L. W and Bravenboer, B and ten Napel, C. H. H and Kootstra, G. J and Sprenger, H. G and ... and DAD Study Grp and D:A:D Study Group
Lancet, The, ISSN 0140-6736, 2008, Volume 371, Issue 9622, pp. 1417 - 1426